Varenicline improves mood and cognition during smoking abstinence.
Varenicline improves mood and cognition during smoking abstinence.
复制标题
DOI：
10.1016/j.biopsych.2008.08.028
复制
发表时间：
2009-01-15
影响因子：
10.6
通讯作者：
Lerman, Caryn
中科院分区：
文献类型：
--
作者：
Patterson, Freda;Jepson, Christopher;Strasser, Andrew A.;Loughead, James;Perkins, Kenneth A.;Gur, Ruben C.;Frey, Joseph M.;Siegel, Steven;Lerman, Caryn
神经元烟碱乙酰胆碱受体（nAChR）是一系列神经精神疾病（包括尼古丁依赖）药物开发工作的关键目标。伐尼克兰是一种α4β2 nAChRs的部分激动剂，是一种新的有效的尼古丁依赖药物。它对尼古丁戒断的情感和认知方面的影响尚未得到很好的表征。67名寻求治疗的吸烟者在双盲受试者内交叉设计中接受伐尼克兰（× 21天）和安慰剂（× 21天）给药。在药物启动期（第1-10天）后，有一个为期3天的强制戒烟期（第11-13天），在此期间评估主观症状和认知表现。参与者再次暴露于计划的吸烟失效（第14天），并在每个药物治疗期内随访数天（第15-21天）。与安慰剂相比，在伐尼克兰治疗期间，戒断症状（p= 0.04）、吸烟欲望（p<0.001）和负面情绪（p= 0.01）显著减少，强制戒烟期间积极情绪（p= 0.046）、持续注意力（p= 0.018）和工作记忆（p= 0.001）水平显著增加。伐尼克兰还显著降低了预定吸烟时间的主观奖励效应（例如，满意度、缓解、喜欢）（p=.003）。药物对计划戒烟后戒烟天数的影响取决于治疗顺序（p= 0.001）;在第一阶段接受安慰剂的参与者中，伐尼克兰增加了随访期间的戒烟天数。这些数据确定了伐尼克兰的新的情感和认知效应，并可能对其他神经精神疾病的药物开发产生影响。
Neuronal nicotinic acetylcholine receptors (nAChRs) are a key target in medication development efforts for a range of neuropsychiatric disorders, including nicotine dependence. Varenicline, a partial agonist at the α4β2 nAChRs, is a new efficacious medication for nicotine dependence. Its effects on the affective and cognitive dimensions of nicotine withdrawal have yet to be well characterized. Sixty-seven treatment-seeking smokers were administered varenicline (× 21 days) and placebo (× 21 days) in a double-blind within-subject cross-over design. Following the medication run-up phase (days 1–10), there was a 3-day mandatory smoking abstinence phase (days 11–13) during which subjective symptoms and cognitive performance were assessed. Participants were re-exposed to a scheduled smoking lapse (day 14) and followed for days to lapse (days 15–21) in each medication period. In the varenicline period, compared to placebo, withdrawal symptoms (p=.04), smoking urges (p<.001), and negative affect (p=.01) were significantly reduced, and levels of positive affect (p=.046), sustained attention (p=.018) and working memory (p=.001) were significantly greater during mandatory abstinence. Varenicline also significantly reduced the subjective rewarding effects of the scheduled smoking lapse (e.g., satisfaction, relief, liking) (p=.003). Medication effects on days to lapse following the scheduled smoking lapse were dependent on treatment order (p=.001); among participants who received placebo in the first period, varenicline increased days of abstinence in the follow-up period. These data identify novel affective and cognitive effects of varenicline, and may have implications for medication development for other neuropsychiatric conditions.
登录
查看更多内容
影响因子：
4.4
作者：
Lerman, C;Audrain, J;Caporaso, N
通讯作者：
Caporaso, N
影响因子：
4.2
作者：
Krishnan-Sarin, Suchitra;Reynolds, Brady;Potenza, Marc N.
通讯作者：
Potenza, Marc N.
影响因子：
5.3
作者：
Kenny, PJ;Markou, A
通讯作者：
Markou, A
影响因子：
4.5
作者：
Kurtz, MM;Wexler, BE;Bell, MD
通讯作者：
Bell, MD
DOI：
10.1073/pnas.041582598
发表时间：
2001-02-27
影响因子：
11.1
作者：
Labarca, C;Schwarz, J;Lester, HA
通讯作者：
Lester, HA